Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

Bullboard Posts

Comment by carduon Jan 03, 2005 7:00pm

249 Views

Post# 8381993

RE: Next support is $4.08 US

Look guys and girls.I'm a senior citizen and have seen many friends and relatives go down to the dreaded disease (probably more than most). The company CANNOT release any results UNTIL the regulatory authorities allow them to do so. All the gnashing of teeth at the slow progress of the trials are beyond the company's ability to respond. Let's all just calm down and wait for the results. Hopefully, alleviation of suffering will come to many people if this treatment bears fruition.

Bullboard Posts

The top 5 mining dividend stocks in Canada